After five years building and advancing a pharmaceutical pipeline that proved difficult to fund, Christopher Moreau decided it was time to find a new cash flow focused path in healthcare that could provide explosive returns for investors. The result is Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) — a rebranded, refocused company with a singular mission: to build the United States’ first dedicated brain PET scan diagnostic network, starting with a flagship clinic in Florida set to open in September.
“When new investors come to the story, they will discover a new, exciting and compelling story says Moreau, the company’s CEO. “This is really a fresh start and a new direction.”
The rebrand from Algernon Health reflects both a change in identity and a change in strategy. Drug repurposing, the company’s original focus, is capital-intensive by nature, and access to that capital proved elusive for a CSE-listed firm locked out of US institutional funds because they are unable to buy or invest in CSE listed stocks. Nuclear medicine and neuroimaging, Moreau concluded, offered a more accessible path to building a sustainable, cash-generating healthcare business. Whether he’s right remains to be seen — but the first clinic will offer an early test.
Why brain diagnostics, and why now
The move into neuroimaging wasn’t arbitrary. Several converging developments made the sector look compelling. First, the FDA approved two antibody therapies for Alzheimer’s disease targeting amyloid plaque buildup in the brain, but accessing either treatment requires diagnostic confirmation through a brain PET scan or spinal tap. That requirement has created a surge in demand among the roughly seven million Americans currently living with Alzheimer’s. Second, Medicare and Medicaid removed a previous once-in-a-lifetime limit on brain PET scans. Third, the FDA approved a new brain-only PET scanner that Grey Matters can access through a partnership with Catalyst Med Tech.
Meanwhile, neurological imaging has long been deprioritized by hospitals and traditional imaging centers. Standard PET-CT systems are primarily configured for abdominal cancer and cardiac diagnostic and theranostic imaging — only about 10% of scans today are neurological. Neuro scans take longer, generating less revenue for facilities with competing priorities. The result, Moreau argues, is a growing gap between demand and available capacity.
A PET scanner that changes the patient experience
At the center of Grey Matters’ model is technology that looks considerably different from a conventional PET/CT machine. Traditional systems weigh up to 11,000 pounds, cost between $3 million and $5 million and require hundreds of thousands more in installation and lead wall and door protection. They also require patients to lie flat on a narrow table and move into a large halo structure, which can be distressing for a healthy person, never mind patients managing memory loss or cognitive decline. Many neuro-degenerative disease patients are older and the movement of the scanner table into the scanner can also cause dizziness and claustrophobic events.
The scanner Grey Matters has partnered to deploy costs approximately US$850,000, plugs into the wall and requires only around $10,000 in lead protection. Instead of lying down and moving into a tunnel, patients sit upright in a chair while the scanner moves around them, reducing claustrophobia and dizziness. Because the system does not require a CT component, patients receive approximately 25% less radiation than from a conventional scan.
The economics, according to management projections, are also favorable. After isotope costs, the company would realize net income of roughly US$2,100 per scan, with billing at approximately $4,500 covered by Medicare, Medicaid and private insurance. On those figures, breaking even would require only about 1.6 scans per day, though translating early projections into consistent patient volume is precisely the execution challenge the first clinic will need to demonstrate.
NovaScan’s Florida debut
Grey Matters’ first NovaScan clinic will open within the medical offices of HCA Florida University Hospital in Davie, which currently outsources all PET imaging for its neurology patients. The clinic will be embedded directly on hospital property, with space already built and suited to the company’s needs. Grey Matters will also base its corporate headquarters there.
Each clinic is designed to run lean: approximately 1,800 square feet, two core staff members including a certified nuclear medicine technologist and an administrator, and a concierge-style model built around older patients who make up the majority of the patient base.
Three additional Florida locations are planned by Q2, 2027. Physician outreach is already underway, targeting neurologists, geriatricians, psychiatrists and primary care physicians within roughly a 90-minute radius of each clinic. A marketing alliance with GE Healthcare will help introduce NovaScan into established referral networks, while a partnership with American Radiology covering 80 radiologists, specializing in neuro-diseases, who will read NovaScan images and provide a diagnosis, underpins the clinical credibility of the model.
A different investment thesis
For investors, the Grey Matters story represents a meaningful shift in what they are being asked to bet on. Drug development companies raise capital continuously to fund trials that can take years to reach any commercial milestone. The NovaScan model is built around operational cash flow from day one.
Scaling to the company’s stated ambition of several hundred locations nationwide will require consistent execution, sustained access to isotope supply, insurance credentialing across multiple markets and capital for expansion. The company’s stock is currently near historical lows, which Moreau frames as a potential entry point ahead of what he expects will be a demonstrable commercial milestone before year-end.
The CEO is candid about the road to get here. “Sometimes you have to drag people through the rose bushes a bit before they understand all of the important critical details of a new business plan,” he said. “We think we have a better mousetrap and to understand that, you need to explain how the current standard of care works and how we think it is coming up short and therein lies the opportunity.”
The first clinic will determine whether the new one is worth the thorns.
Aashura is the Lead Researcher at CryptoListed.net. As a dedicated crypto investor and analyst since 2018, he specializes in creating clear, data-driven guides that help users navigate the market safely. Follow his latest insights on Twitter @[YourHandle].
